

Basic science (August 2006)

1. Ai LB, Kim WJ, Kim TY, Fields CR, Massoll NA, Robertson KD, Brown KD. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. *Cancer Res* 2006; **66**: 7899–7909.
2. Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P, Wei WZ, Cavallo F. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. *Cancer Res* 2006; **66**: 7734–7740.
3. Beisner J, Buck MB, Fritz P, Dippon J, Schwab M, Brauch H, Zugmaier G, Pfizenmaier K, Knabbe C. A novel functional polymorphism in the transforming growth factor-beta(2) gene promoter and tumor progression in breast cancer. *Cancer Res* 2006; **66**: 7554–7561.
4. Buterin T, Koch C, Naegeli H. Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. *Carcinogenesis* 2006; **27**: 1567–1578.
5. Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai LM, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. *Int J Cancer* 2006; **119**: 944–954.
6. Cebrian A, Pharoah PD, Ahmed S, Ropero S, Fraga MF, Smith PL, Conroy D, Luben R, Perkins B, Easton DF, Dunning AM, Esteller M, Ponder BAJ. Genetic variants in epigenetic genes and breast cancer risk. *Carcinogenesis* 2006; **27**: 1661–1669.
7. Cook AC, Chambers AF, Turley EA, Tuck AB. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. *J Biol Chem* 2006; **281**: 24381–24389.
8. Cotroneo MS, Merry GM, Haag JD, Lan H, Shepel LA, Gould MN. The Mcs7 quantitative trait locus is associated with an increased susceptibility to mammary cancer in congenic rats and an allele-specific imbalance. *Oncogene* 2006; **25**: 5011–5017.
9. Cuevas BD, Winter-Vann AM, Johnson NL, Johnson GL. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. *Oncogene* 2006; **25**: 4998–5010.
10. Deans AJ, Khanna KK, McNees CJ, Mercurio C, Heierhorst J, McArthur GA. Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. *Cancer Res* 2006; **66**: 8219–8226.
11. Dejmeck J, Saffholm A, Nielsen CK, Andersson T, Leandersson K. Wnt-5a/Ca²⁺-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1 alpha signaling in human mammary epithelial cells. *Mol Cell Biol* 2006; **26**: 6024–6036.
12. Dien J, Amin HM, Chiu N, Wong W, Frantz C, Chiu B, Mackey JR, Lai R. Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. *Am J Pathol* 2006; **169**: 633–642.
13. Dizin E, Gressier C, Magnard C, Ray H, Decimo D, Ohlmann T, Dalla Venezia N. BRCA1 interacts with poly(A)-binding protein – implication of BRCA1 in translation regulation. *J Biol Chem* 2006; **281**: 24236–24246.
14. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. *New Engl J Med* 2006; **355**: 560–569.
15. Garcia-Pedrero JM, Kiskinis E, Parker MG, Beldandia B. The SWI/SNF chromatin remodeling subunit BAF57 is a critical regulator of estrogen receptor function in breast cancer cells. *J Biol Chem* 2006; **281**: 22656–22664.
16. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB. Hypoxia-inducible factor-1 alpha-expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human

- breast cancer. *Clin Cancer Res* 2006; **12**: 4562–4568.
17. Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, Chaffanet M, Birnbaum D, Bertucci F. Prognosis and gene expression profiling of 20q13-amplified breast cancers. *Clin Cancer Res* 2006; **12**: 4533–4544.
 18. Guo WJ, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. *Cell* 2006; **126**: 489–502.
 19. Guo X, Hartley RS. HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. *Cancer Res* 2006; **66**: 7948–7956.
 20. Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundan T, Mannermaa A, Borresen-Dale AL, Borg A, Barkardottir RB, Petrini J, Winqvist R. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. *Carcinogenesis* 2006; **27**: 1593–1599.
 21. Jacobsen BM, Harrell JC, Jedlicka P, Borges VF, Varella-Garcia M, Horwitz KB. Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. *Cancer Res* 2006; **66**: 8274–8279.
 22. Kao J, Pollack JR. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. *Gene Chromosome Cancer* 2006; **45**: 761–769.
 23. Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. *Cancer Res* 2006; **66**: 7849–7853.
 24. Lin X, Yu YN, Zhao HP, Zhang YY, Manela J, Tonetti DA. Overexpression of PKC alpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. *Carcinogenesis* 2006; **27**: 1538–1546.
 25. Macedo LF, Guo ZY, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. *Cancer Res* 2006; **66**: 7775–7782.
 26. Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA, Strom BL, Burkman RT, Ursin G, Deapen D, Weiss LK, Folger S, Madeoy JJ, Friedrichsen DM, Suter NM, Humphrey MC, Spirtas R, Ostrander EA. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. *Cancer Res* 2006; **66**: 8297–8308.
 27. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu positive breast cancer. *Cancer Res* 2006; **66**: 8266–8273.
 28. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GCM, Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. *Cancer Res* 2006; **66**: 8109–8115.
 29. McGuire V, John EM, Felberg A, Haile RW, Boyd NF, Thomas DC, Jenkins MA, Milne RL, Daly MB, Ward J, Terry MB, Andrulis IL, Knight JA, Godwin AK, Giles GG, Southey M, West DW, Hopper JL, Whittemore ASGAKI. No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years. *Cancer Epidemiol Biomark Prevent* 2006; **15**: 1565–1567.
 30. Menendez JA, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemo sensitivity effect in the absence of Her-2 overexpression. *J Clin Oncol* 2006; **24**: 3735–3746.
 31. Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. *Nat Cell Biol* 2006; **8**: 815–25.
 32. Oestergaard MZ, Tyrer J, Cebrian A, Shah M, Dunning AM, Ponder BAJ, Easton DF, Pharoah PDP. Interactions between genes involved in the antioxidant defence system and breast cancer risk. *Br J Cancer* 2006; **95**: 525–531.
 33. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol* 2006; **24**: 3726–3734.
 34. Palmer JR, Wise LA, Hatch EE, Troisi R, Titus-Ernstoff L, Strohsnitter W, Kaufman R, Herbst AL, Noller KL, Hyer M, Hoover RN. Prenatal diethylstilbestrol exposure and risk of breast cancer. *Cancer Epidemiol Biomark Prevent* 2006; **15**: 1509–1514.
 35. Poola I, Shokrani B, Bhatnagar R, DeWitty RL, Yue QQ, Bonney G. Expression of carcino-embryonic antigen cell adhesion molecule 6

- oncoprotein in atypical ductal hyperplastic tissues is associated with the development of invasive breast cancer. *Clin Cancer Res* 2006; **12**: 4773–4783.
36. Qi XM, Tang J, Loesch M, Pohl N, Alkan S, Chen G. p38 gamma mitogen activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion. *Cancer Res* 2006; **66**: 7540–7547.
 37. Quintela-Fandino M, Lopez JM, Hitt R, Gamarra S, Jimeno A, Ayala R, Hornedo J, Guzman C, Gilsanz F, Cortes-Funes H. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. *J Clin Oncol* 2006; **24**: 3611–3618.
 38. Radke I, Gotte M, Kersting C, Mattsson B, Kiesel L, Wulfiging P. Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. *Br J Cancer* 2006; **95**: 347–354.
 39. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman NGABCS. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility. *Nat Genet* 2006; **38**: 873–875.
 40. Reynolds PA, Sigaroudinia M, Zardo G, Wilson MB, Benton GM, Miller CJ, Hong CB, Fridlyand J, Costello JF, Tlsty TD. Tumor suppressor p16(INK4A) regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. *J Biol Chem* 2006; **281**: 24790–24802.
 41. Schaffer BS, Lachel CM, Pennington KL, Murrin CR, Strecker TE, Tochacek M, Gould KA, Meza JL, McComb RD, Shull JD. Genetic bases of estrogen-induced tumorigenesis in the rat: mapping of loci controlling susceptibility to mammary cancer in a Brown Norway × ACI intercross. *Cancer Res* 2006; **66**: 7793–7800.
 42. Shioda T, Chesnes J, Coser KR, Zou LH, Hur J, Dean KL, Sonnenschein C, Soto AM, Isselbacher KJ. Importance of dosage standardization for interpreting transcriptomal signature profiles: evidence from studies of xenoestrogens. *Proc Natl Acad Sci USA* 2006; **103**: 12033–12038.
 43. Singh R, Paterson Y. Vaccination strategy determines the emergence and dominance of CD8(+) T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. *Cancer Res* 2006; **66**: 7748–7757.
 44. Sommerfeldt N, Schutz F, Sohn C, Forster J, Schirrmacher V, Beckhove P. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. *Cancer Res* 2006; **66**: 8258–8265.
 45. Stahl M, Ge CH, Shi SL, Pestell RG, Stanley P. Notch1-induced transformation of RKE-1 cells requires up-regulation of cyclin D1. *Cancer Res* 2006; **66**: 7562–7570.
 46. Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, Jirstrom K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. *Clin Cancer Res* 2006; **12**: 4614–4618.
 47. Stevens TA, Meech R. BARX2 and estrogen receptor-alpha (ESR1) coordinately regulate the production of alternatively spliced ESR1 isoforms and control breast cancer cell growth and invasion. *Oncogene* 2006; **25**: 5426–5435.
 48. Surowiak P, Materna V, Gyorffy B, Matkowski R, Wojnar A, Maciejczyk A, Paluchowski P, Dziegiel P, Pudelko M, Kornafel J, Dietel M, Kristiansen G, Zabel M, Lage H. Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. *Br J Cancer* 2006; **95**: 339–346.
 49. Thusbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. *J Clin Oncol* 2006; **24**: 3747–3755.
 50. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a cross-sectional and longitudinal evaluation. *Br J Cancer* 2006; **95**: 506–514.
 51. Walser TC, Rifat S, Ma XR, Kundu N, Ward C, Goloubeva O, Johnson MG, Medina JC, Collins TL, Fulton AM. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. *Cancer Res* 2006; **66**: 7701–7707.
 52. Warren R, Skinner J, Sala E, Denton E, Dowsett M, Folkard E, Healey CS, Dunning A, Doody D, Ponder B, Luben RN, Day NE, Easton D. Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. *Cancer Epidemiol Biomark Prevent* 2006; **15**: 1502–1508.
 53. Wolf I, O’Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY, Koeffler HP.

- 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. *Cancer Res* 2006; **66**: 7818–7823.
54. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulis V, Mavroudis D. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. *J Clin Oncol* 2006; **24**: 3756–3762.
55. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L, Vadlamudi RK, Jones FE. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. *Cancer Res* 2006; **66**: 7991–7998.

Prepared by
R. Sutherland, J. Scorer
Cancer Research Program
Garvan Institute of Medical Research
Darlinghurst, NSW, Australia